National Comprehensive Cancer Network
NCCN Guidelines and Compendium Updated
Flash Update Sent August 20, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Multiple Myeloma. The NCCN Guidelines are currently available as Version 1.2013.
- Myeloma Therapy
- For therapy with bortezomib-based regimens, the NCCN Panel added, "Consider using subcutaneous bortezomib for patients with pre-existing or high-risk peripheral neuropathy" (footnote 2, MYEL-D).
- Maintenance Therapy
- Maintenance therapy with lenalidomide was changed from a category 2A to a category 1 recommendation (MYEL-D, page 1 of 2).
- Salvage Therapy (MYEL-D, page 2 of 2)
- The following were added to the list of "preferred salvage regimens":
- Bortezomib/thalidomide/dexamethasone (category 2A)
- Carfilzomib (category 2A), with a footnote stating that this agent is "Indicated for patients who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy."
- The following regimens were added to the list of "other salvage regimens":
- Bortezomib/vorinostat (category 2A)
- Lenalidomide/bendamustine/dexamethasone (category 2A)
- The Discussion section has been updated to reflect the changes in the algorithm.
- NCCN has published new NCCN Guidelines for Patients™: Multiple Myeloma. The NCCN Guidelines for Patients™ are currently available as Version 1.2012.
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.